Search

Astellas Pharma Inc.
  • Top MenuAbout
    Corporate Strategic Plan 2021
    Corporate Strategic Plan 2021 (CSP2021) maps the next five years of our journey.
    Read More
    • From the CEO
    • Philosophy
      • Astellas Charter of Corporate Conduct, Group Code of Conduct
    • VISION
    • At a Glance
      • Subsidiaries & Locations
      • Our Business
      • Main Products
      • History
      • Management
    • Board of Directors
    • Global Management Structure
    • Corporate Governance Materials
      • Risk Management
    • Policies & Position Statements
    • Ethics & Compliance
      • Structure to Promote Ethics and Compliance
      • Primary Areas of Focus
      • Elements of Astellas’ Global Ethics & Compliance Program
      • Enhancing and Sustaining an Ethical and Compliant Culture at Astellas
  • Top MenuInnovation
    Innovation
    We pursue cutting-edge science to continuously provide innovative treatment options.
    Read More
    • R&D Strategy
      • Drug Research
      • Major Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Grants for Education and General Research
        • Grants to HCOs to Support HCP Attendance at Congresses
    • Areas of Interest
      • Primary Focus
        • Genetic Regulation
        • Immuno-Oncology
        • Blindness & Regeneration
        • Mitochondria
        • Targeted Protein Degradation
      • Primary Focus Candidates
        • Immune Homeostasis
      • Exploratory Research
        • Targeted Therapeutics for Auditory Regeneration
        • Autophagy
        • Bispecific Immune Cell Engager
        • Engineered Phage Therapy
        • Specific Treg
        • Direct Reprogramming
        • Innate Immune Regulation
      • Cell Therapy
    • Digital Transformation
      • DX Initiatives Throughout the Value Chain
    • New Healthcare Solutions Beyond Medicine (Rx+®)
      • Investigational Near-Infrared Fluorescence Imaging Agent
      • Clinically Relevant Holistic Solutions Mobile Healthcare Application
      • Innovation of Chronic Heart Failure Patient Management
    • Partnering
  • Top MenuInvestors
    Investor Relations
    You can access to IR related information including IR Library, Financial Information, Corporate Strategic Plan.
    Read More
    • Topics
      • Corporate Strategic Plan 2021
      • Integrated Report
        • Archives
      • Astellas’ ESG Initiatives
    • Financial Information
    • IR Library
      • Business Results
      • Overview of R&D Pipeline
      • IR Meetings
      • Consolidated Financial Statements and Footnotes
      • Corporate Governance Materials
    • IR Calendar
    • Stock & Rating Information
      • Shareholders Meeting
      • Shareholder Return
      • Current Share Status
      • Chart
      • Issuer Rating
      • Analyst Coverage
    • Cautionary Statement
    • Introducing Astellas to Individual Investors
  • Top MenuSustainability
    Sustainability Direction
    We have set Med-term Priorities, Initiatives, and Our Commitments by FY2025 as for Two pillars and Environmental Sustainability.
    Read More
    • Message from CEO
    • Sustainability Approach
      • Sustainability Governance
      • Key Issues and Materiality
      • Sustainability Direction
      • ISO26000
      • Astellas’ SDG Initiatives
      • United Nations Global Compact
      • Stakeholder Communications
      • Awards & Recognition
    • Access to Health
      • Access to Health of Astellas
      • Access to Medicines
      • Healthcare Systems Strengthening
      • Tuberculosis and Malaria
      • Research Activities on NTDs
      • Development for Schistosomiasis
      • GHIT Fund
      • Access Accelerated
      • Action on Fistula
      • Patient Support Activity
      • Medical Science Advancement
      • Astellas Global Health Foundation
      • Access to Medicine Index Report
    • Environment
      • Environment Initiatives
      • EHS Management
        • ISO certification status of Astellas manufacturing sites
      • Environmental Action Plan and Compliance
      • Climate Change Measures
        • Scope 3 emissions (past 3 years)
      • Disclosure based on TCFD
      • Energy Consumption
      • Sustainable Biodiversity
        • Biodiversity and Astellas An Enlarged Version
        • The Biodiversity Burden Index and Revenue
      • Resource Recycling
      • Preventing Pollution
        • Further information on PRTR system
      • Environmental Impact of Products and Countermeasures
      • Archive (EHS Report)
      • Environmental Accounting
        • Environment-related Investments and Expenses
      • Reporting coverage, methods
    • Astellas and Society
      • Our People
        • HR Vision, Talent and Organization Management
        • Engagement and Diversity, Equity & Inclusion
        • Occupational Health & Safety
        • Promoting Health Management
        • Major Activities and Programs (Japan)
      • Sustainability in Business Practice
        • Sustainable Procurement Initiatives
        • Research Initiatives
        • Clinical Development Initiatives
        • Technological Development and Production Initiatives
        • Distribution and Sales Initiatives
      • Respect for Human Rights
      • Community Engagement
        • Flying Star Fund
        • Employee Contributions to the Local Community
      • Governance
    • Governance
    • ESG Data
      • ESG Data Environment
      • ESG Data Social
      • ESG Data Governance
  • Top MenuNews
    News Room
    Check the latest news and our people's stories.
    Read More
    • ALL News
    • Stories
    • Media Library

Stakeholders menu

  • Partnering
    • Why Partner with Astellas
    • Partnering Teams
    • Testimonies from our Partners
    • Registration Form
  • Careers
  • Contact Us

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
  • GLOBAL
  • 日本
  1. Home
  2. Investors
  3. IR Library
  4. Overview of R&D Pipeline

Overview of R&D Pipeline

Important Notice

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

OK
logo
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Cancel Click here to leave this site.

We introduce the progress of our clinical development projects called "R&D pipeline". We update R&D pipeline 4 or 5 times annually in our quarterly performance reports.

 

Overview of R&D Pipeline [February 6, 2023] (394KB)
footer logofooter solgan

Follow us on social media

Linkedin Logo Youtube Logo

Bottom footer menu

  • SITE MAP
  • PRIVACY POLICY
  • COOKIES POLICY
  • ACCESSIBILITY
  • TERMS OF USE
  • CONTACT US
  • DISASTER INFORMATION FOR EMPLOYEES
© Astellas Pharma Inc.

Update cookie preferences